Advances in multiple myeloma therapy during two past decades
Status PubMed-not-MEDLINE Language English Country Netherlands Media electronic-ecollection
Document type Journal Article, Review
PubMed
25210597
PubMed Central
PMC4151869
DOI
10.1016/j.csbj.2014.05.005
PII: S2001-0370(14)00006-3
Knihovny.cz E-resources
- Keywords
- ASCT, Bortezomib, Lenalidomide, Multiple myeloma,
- Publication type
- Journal Article MeSH
- Review MeSH
Multiple myeloma (MM) is a clonal B-cell malignancy characterized by aberrant expansion of plasma cells within bone marrow and extramedullary sites. It is one of the most common haematological malignancies; it accounts for 1.4% of all tumours and is responsible for 2% of cancer-related mortality. Over the last decades, the paradigm of MM therapy has changed dramatically - from the conventional combination of oral melphatan + prednisone, high-dose chemotherapy with stem cell (ASCT) support for younger patients to the present paradigm with the use of one (or more) of 3 major new targeted agents - the first-in class proteasome inhibitor bortezomib, the immunomodulatory drug thalidomide, and its more potent derivative lenalidomide. Their use as a part of initial therapy is associated with high overall response rates as well as high rates of complete response (CR), both for elderly patients unable to undergo ASCT and for younger patients treated prior to ASCT. Altogether, the advent of novel agents has resulted in a 50% improvement in median survival. Moreover, the development of new drug classes based on preclinical rationale and the introduction of next-generation agents are likely to further expand treatment options and improve outcomes for especially relapsed MM. This review highlights important historic landmarks as well as more recent events that have played an important role in the evolution of myeloma targeted therapy.
See more in PubMed
Ludwig H., Durie B., Bolejack V., Turesson I., Kyle R.A., Blade J. Myeloma in patients under age 50 presents with more favorable features and shows better survival: an analysis of 10,549 patients from the International Myeloma Working Group. Blood. 2008;111:4039–4047. PubMed PMC
Kumar S.K., Rajkumar S.V., Dispenzieri A., Lacy M.Q., Hayman S.R., Buadi F.K. Improved survival in multiple myeloma and the impact of novel therapies. Blood. 2008;111(5):2516–2520. PubMed PMC
Richardson P.G., Barlogie B., Berenson J., Singhal S., Jagannath S., Irwin D., Rajkumar S.V. A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med. 2003;348:2609–2617. PubMed
Richardson P.G., Sonneveld P., Schuster M.W., Irwin D., Stadtmauer E.A., Facon T. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med. 2005;352:2487–2498. PubMed
Mitsiades N., Mitsiades C.S., Richardson P.G., Poulaki V., Tai Y.T., Chauhan D. The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: therapeutic applications. Blood. 2003;101:2377–2380. PubMed
Richardson P.G., Mitsiades C., Schlossman R., Ghobrial I., Hideshima T., Munshi N. Bortezomib in the front-line treatment of multiple myeloma. Expert Rev Anticancer Ther. 2008;8:1053–1107. PubMed
Berenson J.R., Yang H.H., Sadler K., Jarutirasarn S.G., Vescio R.A., Mapes R. Phase I/II trial assessing bortezomib and melphalan combination therapy for the treatment of patients with relapsed or refractory multiple myeloma. J Clin Oncol. 2006;24:937–944. PubMed
Mateos M.V., Hernández J.M., Hernández M.T., Gutiérrez N.C., Palomera L., Fuertes M. Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: results of a multicenter phase 1/2 study. Blood. 2006;108:2165–2172. PubMed
San Miguel J.F., Schlag R., Khuageva N.K., Dimopoulos M.A., Shpilberg O., Kropff M. VISTA trial investigators: bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. N Engl J Med. Aug 28 2008;359(9):906–917. PubMed
Dimopoulos M.A., Richardson P.G., Schlag R., Khuageva N.K., Shpilberg O., Kastritis E. VMP (Bortezomib, Melphalan, and Prednisone) is active and well tolerated in newly diagnosed patients with multiple myeloma with moderately impaired renal function, and results in reversal of renal impairment: cohort analysis of the phase III VISTA study. J Clin Oncol. 2009 PubMed
Mateos M.V., Richardson P.G., Schlag R., Khuageva N.K., Dimopoulos M.A., Shpilberg O. Bortezomib plus melphalan and prednisone compared with melphalan and prednisone in previously untreated multiple myeloma: updated follow-up and impact of subsequent therapy in the phase III VISTA trial. J Clin Oncol. May 1 2010;28(13):2259–2266. [Epub 2010 Apr 5] PubMed
Harousseau J.L., Palumbo A., Richardson P., Schlag R., Dimopoulos M., Shpilberg O. Superior outcomes associated with complete response in newly diagnosed multiple myeloma patients treated with non-intensive therapy: analysis of the phase 3 VISTA study of bortezomib plus melphalan–prednisone versus melphalan–prednisone. Blood. 2010;116(19):3743–3750. PubMed
Sonneveld P., Schmidt-Wolf I.G., van der Holt B., El Jarari L., Bertsch U., Salwender H. Bortezomib induction and maintenance treatment in patients with newly diagnosed multiple myeloma: results of the randomized phase III HOVON-65/GMMG-HD4 trial. J Clin Oncol. Aug 20 2012;30(24):2946–2955. [Epub 2012 Jul 16] PubMed
Scheid C., Sonneveld P., Schmidt-Wolf I.G., van der Holt B., el Jarari L., Bertsch U. Bortezomib before and after autologous stem cell transplantation overcomes the negative prognostic impact of renal impairment in newly diagnosed multiple myeloma: a subgroup analysis from the HOVON-65/GMMG-HD4 trial. Haematologica. Jan 2014;99(1):148–154. PubMed PMC
Richardson P.G., Lonial S., Jakubowiak A. Lenalidomide, bortezomib, and dexamethasone in patients with newly diagnosed multiple myeloma: encouraging efficacy in high risk groups with updated results of a phase I/II study [abstract 92] Blood. 2008;112:41.
Kumar S., Flinn I., Richardson P.G., Hari P., Callander N., Noga S.J. Randomized, multicenter, phase 2 study (EVOLUTION) of combinations of bortezomib, dexamethasone, cyclophosphamide, and lenalidomide in previously untreated multiple myeloma. Blood. 2012;119(19):4375–4382. PubMed
Dimopoulos M., Spencer A., Attal M., Prince H.M., Harousseau J.L., Dmoszynska A. Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma. N Engl J Med. 2007;357:2123–2132. PubMed
Weber D.M., Chen C., Niesvizky R., Wang M., Belch A., Stadtmauer E.A. Multiple Myeloma (009) Study Investigators. Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America. N Engl J Med. Nov 22 2007;357(21):2133–2142. PubMed
Rajkumar S.V., Jacobus S., Callander N.S., Fonseca R., Vesole D.H., Williams M.E. Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial. Lancet Oncol. 2010;11:29–37. PubMed PMC
Palumbo A., Hajek R., Delforge M., Kropff M., Petrucci M.T., Catalano J. Continuous lenalidomide treatment for newly diagnosed multiple myeloma. N Engl J Med. 2012;366:1759–1769. PubMed
Spencer A., Prince H.M., Roberts A.W., Prosser I.W., Bradstock K.F., Coyle L. Consolidation therapy with low-dose thalidomide and prednisolone prolongs the survival of multiple myeloma patients undergoing a single autologous stem-cell transplantation procedure. J Clin Oncol. 2009;27:1788–1793. PubMed
Morgan G.J., Jackson G.H., Davies F.E. Maintenance thalidomide may improve progression free but not overall survival; results from the Myeloma IX maintenance randomisation [abstract 656] Blood. 2008;112:245.
Attal M., Lauwers-Cances V., Marit G., Caillot D., Moreau P., Facon T. Lenalidomide maintenance after stem-cell transplantation for multiple myeloma. N Engl J Med. May 10 2012;366(19):1782–1791. PubMed
McCarthy P.L., Owzar K., Hofmeister C.C., Hurd D.D., Hassoun H., Richardson P.G. Lenalidomide after stem-cell transplantation for multiple myeloma. N Engl J Med. 2012;366:1770–1781. PubMed PMC
Attal M., Lauwers-Cances V., Marit G. Lenalidomide maintenance after stem-cell transplantation for multiple myeloma: follow-up analysis of the IFM 2005-02 trial. Blood. 2013;122:406.
Mateos M.V., Oriol A., Martínez-López J., Gutiérrez N., Teruel A.I., de Paz R. Bortezomib, melphalan, and prednisone versus bortezomib, thalidomide, and prednisone as induction therapy followed by maintenance treatment with bortezomib and thalidomide versus bortezomib and prednisone in elderly patients with untreated multiple myeloma: a randomised trial. Lancet Oncol. Oct 2010;11(10):934–941. PubMed
Richardson P.G., Mitsiades C.S., Laubach J.P., Hajek R., Spicka I., Dimopoulos M.A. Preclinical data and early clinical experience supporting the use of histone deacetylase inhibitors in multiple myeloma. Leuk Res. Jul 2013;37(7):829–837. [Epub 2013 Apr 9] PubMed
Ocio E.M., Richardson P.G., Rajkumar S.V., Palumbo A., Mateos M.V., Orlowski R. New drugs and novel mechanisms of action in multiple myeloma in 2013: a report from the International Myeloma Working Group (IMWG) Leukemia. Nov 20 2013 PubMed PMC